PCSA Processa Pharmaceuticals, Inc.
Healthcare$2.50-5.66%ClosedMarket Cap: $5.7M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
2.74
P/S
0.00
EV/EBITDA
-0.30
DCF Value
$3.49
FCF Yield
-204.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-281.3%
ROA
-312.0%
ROIC
-569.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-3.3M | $-3.4M | $— | — |
| Q4 null | $0.00 | NaN% | $-3.7M | $-3.4M | $— | — |
| FY null | $0.00 | NaN% | $-14.0M | $-13.6M | $— | — |
| Q3 null | $0.00 | NaN% | $-3.5M | $-3.4M | $— | — |
| Q2 null | $0.00 | NaN% | $-4.0M | $-3.9M | $— | — |
| Q1 null | $0.00 | NaN% | $-2.8M | $-2.8M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-2.7M | $-2.7M | $— | — |
| FY null | $0.00 | NaN% | $-12.1M | $-11.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-3.4M | $-3.4M | $— | — |
| Q2 null | $0.00 | NaN% | $-3.1M | $-3.0M | $— | — |
| Q1 null | $0.00 | NaN% | $-2.8M | $-2.7M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-2.5M | $-2.4M | $-32.50 | — |